BioSpace

Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients

Posthoc analyses in women divided by menopausal status show how Novo’s next-generation GLP-1 drug affects key cohorts of patients.

By BioSpace

1 min read
Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights